SILVER SPRING, Md., Aug. 9, 2022 (GLOBE NEWSWIRE) — Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company, today announced that Aziyo co-founder C. Randal (Randy) Mills, Ph.D. has continuously assumed the role of President and Chief Executive Officer. dr. Mills, who is internationally recognized for his contributions to regenerative medicine, has served as the company’s interim CEO since June 2022.
“Since Aziyo’s founding in 2015, Randy and I have worked together to build a business where regenerative medicine is used to the fullest,” said Kevin Rakin, Co-Founder and Executive Chairman. “Randy is a visionary leader with a track record of creating significant shareholder value in regenerative medicine. The Board of Directors and I look forward to working with Randy to realize his vision for this company.”
“We don’t think 1 in 10 women undergoing breast reconstruction will have a serious infection. A pacemaker should also not wear through the fragile skin of a patient with a heart block,” says Dr. Randy Mills, CEO. “We want to change that. We know the impact regenerative medicine can have on patients’ lives – now it’s our job to make it happen.”
For an update on the company’s financial results, performance and vision for the second quarter of 2022, join an extended conference call on Thursday, August 11, 2022 at 4:30 PM Eastern Time / 1:30 PM Pacific Time. Individuals interested in listening to the conference call are required to register online. Participants must register at least 15 minutes before the start of the call. A live and archived webcast of the event will be available in the “investors” section of the Aziyo website at https://investors.aziyo.com/.
Randy Mills, Ph.D.Co-founder of Aziyo Biologics, is an internationally recognized expert in regenerative medicine who has led pioneering biotechnology organizations that have created more than $1 billion in shareholder value for investors. As CEO of Osiris Therapeutics, he commercialized five cell therapy products that generated $1.5 billion in sales and led the company through an IPO that increased shareholder value by 41 times. Osiris was eventually sold to Smith and Nephew for $660 million. dr. Mills was also a co-founder and officer of Regeneration Technologies, where he led operations, R&D, regulation and business development through the IPO, growing annual revenue to $150 million. Randy’s “patient first” leadership style has also helped transform some of the nation’s most cherished medical institutions. dr. Mills has received numerous awards, including being named Ernst & Young Entrepreneur of the Year, one of the world’s 50 most influential people in regenerative medicine and winner of AATB’s Hyatt Memorial Award for Scientific Leadership in Transplantation.
About Aziyo Biologics
Aziyo Biologics is a commercial-stage regenerative medicine company focused on creating next-generation differentiated products and improving outcomes in patients undergoing surgery, with a focus on patients receiving implantable medical devices. Since its founding in 2015, the company has developed a portfolio of commercial products used in cardiovascular, orthopedic and reconstructive specialties. For more information, visit www.Aziyo.com.
Statements in this press release regarding management’s future expectations, beliefs, intentions, goals, strategies, plans or prospects are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the advancement and development of its products and its business potential. Forward-looking statements can be identified by words such as “anticipate,” “believe,” “continue,” “expect,” “target,” “intend,” “may,” “intend,” “potential,” “projects.” ”, “will” and other similar words or expressions, or the negative of such words or similar words or expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors, including, but not limited to, the risks referenced in the “Risk Factors” section of the Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2022, as such factors may be updated from time to time in the Company’s other filings with the Securities and Exchange Commission (“SEC”), which filings are accessible on the SEC’s website at www.sec.gov and the Investors page of the Company’s website at https://investors.azi yo.com. All forward-looking statements speak only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements herein, whether as a result of new information, future events, changed circumstances or otherwise.
Aziyo Biologics, Inc.